Eczema

Eczema is the second most-claimed skin condition in my BVA dataset, and 39.9 percent of the appeals end in a grant. That's more than nine points above the overall grant rate of 30.6 percent across every condition I track. By any honest read of the numbers, the Board is more generous with eczema than with most of what crosses its docket.

That gap is the through-line of this post. Eczema doesn't behave like the typical claim. The diagnosis is usually obvious. A dermatologist with a clinical exam confirms it. The rating ladder under 38 CFR § 4.118 is mechanical: body surface area affected plus how much treatment the veteran needs to keep it under control. And the in-service evidence requirement is forgiving because eczema flares episodically, which makes lay statements unusually powerful. I pulled the regulatory framework under § 4.118, the outcomes across 2,002 BVA eczema cases, the connection-type splits, the C&P adequacy patterns, and the lay-statement effect that doubles grant rates here. The goal is to map what the Board actually rewards on eczema claims and where most denials come from.

TL;DR

• Eczema is the second-largest skin condition in my BVA dataset, 2,002 cases. Outcomes split granted 39.9 percent, denied 27.8 percent, remanded 32.3 percent.
• Strong nexus grants at 93.5 percent. Weak nexus grants at 12.9 percent. Missing nexus grants at 13.6 percent. The cliff is the same cliff that shows up everywhere else.
• C&P exams are flagged inadequate 63.1 percent of the time for eczema, eleven points above the 52 percent overall average.
• Severity is the most common denial reason, 211 cases, ahead of nexus gap at 183. Most veterans underestimate their body surface area coverage.
• Lay statements quoted in the decision are associated with a 54.7 percent grant rate. When they're not quoted, the grant rate falls to 24.0 percent. A 30-point spread.
• The 60 percent rating is the modal high tier among grants, more common than the 30 percent and 50 percent rating combined.

2,002 Cases. Eczema Is Bigger Than Most Realize

Eczema is the largest dermatologic condition I track aside from a couple of broader skin categories, 2,002 cases. Veterans across every era file it, and the Board is processing thousands of these appeals at a steady pace.

The headline outcome split:

• Granted: 799 cases (39.9 percent)
• Denied: 557 cases (27.8 percent)
• Remanded: 646 cases (32.3 percent)

The grant rate is high, more than nine points above the overall BVA grant rate of 30.6 percent. The remand rate of 32.3 percent is in line with the dataset average, which means eczema doesn't get sent back for development more than any other condition. The Board grants more of these claims than the average claim. The bar isn't unusually high. The medicine is usually clear. What separates winning files from losing files is the rating evidence, body surface area documentation, treatment frequency, flare history, and the lay record that pushes the C&P examiner's snapshot into a fair picture of the condition as it actually behaves.

The Four-Tier Rating Schedule Under DC 7806

Eczema is rated under 38 CFR § 4.118, Diagnostic Code 7806. The framework is mechanical in the same way DC 6604 is for COPD, but with different inputs.

DC 7806 tier definitions

The four rating tiers:

• 0 percent: Less than 5 percent of the entire body or less than 5 percent of exposed areas affected, AND no more than topical therapy required during the past 12 months.
• 10 percent: At least 5 percent but less than 20 percent of the body, OR at least 5 percent but less than 20 percent of exposed areas, OR intermittent systemic therapy required for less than six weeks during the past 12 months.
• 30 percent: 20 to 40 percent of the body, OR 20 to 40 percent of exposed areas, OR systemic therapy required for six weeks or more but not constantly during the past 12 months.
• 60 percent: More than 40 percent of the body or exposed areas affected, OR constant or near-constant systemic therapy during the past 12 months.

The schedule tops out at 60 percent. There is no 100 percent rating under DC 7806. A veteran whose eczema is severe enough to interfere with employment can still pursue TDIU under 38 CFR § 4.16 to draw at the 100 percent rate, but the schedular ceiling on the underlying condition is 60.

The schedule has two independent paths to each tier. A veteran can meet a rating either by body surface area or by treatment intensity. Whichever criterion is more favorable applies. That's why a veteran with eczema affecting 12 percent of body surface area but on a course of oral prednisone for ten weeks can land at 30 percent on the treatment path even though the body surface area falls in the 10 percent range. The framework reads as "or" between the criteria, not "and."

Rating-tier distribution among grants

In my dataset, among eczema grants where a rating tier was coded:

• 0 percent: 21 cases
• 10 percent: 116 cases
• 30 percent: 75 cases
• 50 percent: 30 cases (rated via combinations involving DC 7806 and adjacent codes)
• 60 percent: 80 cases (the modal high tier)

The 10 percent rating is the most common single tier. The 60 percent rating shows up more often than the 30 percent rating, which surprised me when I first cut the numbers. The reading is that eczema cases that make it to the Board bifurcate, well-documented mild cases the regional office should have rated higher, and severe cases that needed appellate attention to reach the right schedular ceiling.

The BSA Math and Why Most Veterans Underestimate Their Coverage

Body surface area is where most rating disputes live. The 5/20/40 percent thresholds in DC 7806 apply against the whole-body denominator using the rule of nines, head and neck around 9 percent, each arm around 9 percent, the anterior and posterior trunk around 18 percent each, each leg around 18 percent.

A flare across both forearms and elbows can read as "two patches" subjectively but reads as roughly 6 to 8 percent body surface area on the rule-of-nines framework. That's already at the 10 percent rating threshold. Add the back of the hands, both feet, and the back of the knees, areas where atopic eczema commonly recurs, and the math moves into the 20 to 40 percent zone for the 30 percent rating tier.

The C&P examiner measures body surface area at one moment in time. If the exam happens during a quiet period, the body surface area on the day of the exam reads as 2 to 4 percent and the rating decision lands at 0 or 10 percent. The veteran's actual condition, flaring across a much wider area during episodes, never gets captured. This is the structural reason lay statements move grant rates as much as they do in this condition. The C&P snapshot misses the condition. The lay record fills it in.

The denial reason data backs this up. Across the 557 denied eczema cases, the breakdown by primary classified reason:

• Other: 487 cases
• Severity insufficient: 211 cases
• Nexus gap: 183 cases
• Diagnosis missing: 122 cases
• Service connection missing: 75 cases

Severity insufficient is the largest classified-with-a-specific-reason category. That's two hundred-some veterans whose claim wasn't denied because the Board didn't believe they had eczema or didn't believe it was service-connected. It was denied because the file didn't document enough severity to support a compensable rating. That's a documentation problem, not a medical problem.

Why Inadequate C&P Exams Run at 63 Percent. Way Above Average

Across my full 101,518-condition-record dataset drawn from 49,876 Board decisions, the Board flags C&P exams as inadequate at a 52 percent rate. For eczema, the inadequacy rate is 63.1 percent. That's an eleven-point tilt toward inadequacy specifically for this condition.

The patterns repeat across the decisions I read. The examiner conducts the exam during a quiet period and records body surface area based on what's visible that day, without engaging with the veteran's flare history. The examiner doesn't review the photographs the veteran brought or doesn't request additional documentation. The examiner uses the worst skin category broadly without applying the rule-of-nines math to specific affected areas.

A common failure is the treatment-path documentation. DC 7806 separates topical therapy from systemic therapy because they describe different severity levels. Systemic therapy means oral corticosteroids, immunosuppressants, biologics, or phototherapy administered in courses. A veteran on intermittent prednisone tapers for flares meets the 10 percent treatment criterion even with low body surface area at the time of exam. A veteran on chronic methotrexate or dupilumab meets the 30 percent or 60 percent treatment criterion. The examiner who notes only "topical steroids" without engaging with the systemic medication history produces a report that the Board can flag as inadequate under the Barr v. Nicholson framework.

The 63.1 percent inadequacy rate has real consequences. Across the full dataset, when a C&P exam is flagged inadequate, the case grants or remands at 81.8 percent. When the exam is adequate, the case grants or remands at 39.7 percent. The remand portion is doing most of that work, the Board sends inadequate cases back for a better exam, which is part of why the eczema remand rate is 32.3 percent.

Toxic Exposure and Gulf War: Direct and Undiagnosed-Illness Paths

Eczema and atopic dermatitis are not listed diseases under 38 USC § 1120, 38 CFR § 3.320, § 3.320a, or § 3.320b. Section 1119 can establish covered toxic-exposure service, but it does not by itself create a disease presumption. A veteran with diagnosed eczema may still establish direct service connection, and a qualifying toxic exposure may trigger VA's examination-and-opinion duties under 38 USC § 1168.

The exposure or presumptive categories invoked in my eczema subset break down like this:

• Burn pit: 172 cases
• Gulf War: 164 cases
• Herbicide: 103 cases
• Agent Orange: 58 cases
• Camp Lejeune: 22 cases

These labels show which theories appeared in the Board decisions; they do not establish that eczema was legally presumptive in those cases. Under 38 USC § 1117 and 38 CFR § 3.317, objective skin signs or symptoms may be part of a qualifying Gulf War undiagnosed illness when they cannot be attributed to a known clinical diagnosis. Once the manifestations are attributed to diagnosed eczema, that undiagnosed-illness shortcut does not automatically apply. A direct nexus or another exact service-connection path is still required.

The grant rates by connection type tell a useful story:

• Direct service connection: 961 cases, 54.1 percent grant
• Secondary: 189 cases, 51.3 percent grant
• Presumptive: 179 cases, 50.8 percent grant
• Aggravation: 23 cases, 34.8 percent grant

All three primary connection types grant at roughly 50 to 54 percent for eczema. That's high. For most conditions in my dataset, direct connection grants at 30 to 40 percent. For eczema, direct service connection is both the dominant path and the strongest performer, because eczema typically presents during active service, recruits develop rashes during basic, sailors react to industrial chemicals, soldiers develop atopic flares in harsh climate conditions. The military medical system documents these episodes in routine sick call records, and when the veteran files years later, the in-service onset is usually verifiable from the service treatment records alone.

Lay Statements Double Grant Rates Here. 54.7 Percent vs 24.0 Percent

In my dataset, when the Board's decision quotes from a lay statement, typically the veteran's own description of symptoms, a spouse's description of flares, a fellow service member's recollection of in-service onset, the grant rate for that case is 54.7 percent across 1,058 cases. When no lay statement is quoted, the grant rate is 24.0 percent across 915 cases.

Read that again.

A 30-point spread between the cases where the Board engages with lay evidence and the cases where it doesn't. That's the largest single behavioral predictor I see for the eczema population, and it dwarfs the effect of most clinical factors.

I want to be careful about the causal claim. The Board quotes lay statements when there are good lay statements to quote. A veteran who submits a detailed declaration about flare timing, body surface area during episodes, treatment regimens that have failed, and effects on work and sleep gives the Board something to engage with. A veteran who submits a generic statement gives the Board nothing to quote. Part of the 30-point spread reflects the underlying quality of the file, not just the presence of lay evidence.

But the magnitude is still telling. Eczema is an episodic condition. The C&P examiner sees one snapshot. The treatment notes capture clinic visits. What's missing from the medical record is the actual lived experience of the disease, what it looks like during a flare, how long flares last, what triggers them, how they affect daily functioning. That's exactly what a lay statement can document. And the severity-insufficient denial category, at 211 cases, is largely a lay-statement gap problem in disguise.

The Secondary Connection Lane Most Veterans Miss

The secondary connection lane is worth flagging because it's a path many veterans miss. Eczema can develop secondary to a service-connected condition through several mechanisms, stress-induced flares secondary to PTSD or anxiety, medication-induced dermatitis from drugs prescribed for other service-connected conditions, compromised skin barrier secondary to certain neurologic conditions, or reactions to prostheses or assistive devices secondary to amputations or musculoskeletal injuries.

In the diagnostic code breakdown for the eczema subset, DC 9411 (PTSD secondary) appears in 62 cases. That's the secondary chain in action, eczema rated alongside a PTSD service connection. The full code distribution:

• 7806 (dermatitis/eczema, primary): 272 cases
• 9411 (PTSD secondary): 62 cases
• 7121 (varicose veins): 25 cases
• 8100 (migraine): 21 cases

The 7121 and 8100 codes show up because some eczema cases are part of a combined pattern in which the rating decision spans multiple diagnostic codes. The secondary chain for eczema isn't always obvious from the chart, but it shows up in real claim files often enough that it's worth a clinical conversation before filing.

What I Can't Tell You From This Data

The 2,002 eczema cases in my dataset are the cases that reached the BVA. They aren't all eczema claims VA processes. The grant rate I'm reporting, 39.9 percent, is the BVA grant rate, not the system-wide grant rate. Most eczema claims with clean files get granted at the regional office and never appeal, which means my data over-represents the harder cases. The overall VA grant rate for eczema is almost certainly higher than 39.9 percent.

The dataset codes connection type, nexus quality, and outcome cleanly, but it doesn't reliably code body surface area or treatment intensity as separate variables. I can tell you the modal rating tier among grants, but I can't tell you the modal body surface area at exam. That variable lives in the C&P reports, not in the structured outcomes file.

The dataset also doesn't track which veterans filed for an increase after their initial rating. Eczema is episodic, and a veteran rated at 10 percent in 2018 may flare into the 30 percent range by 2024. Whether and how often those increase claims succeed is something I don't have visibility into from BVA decisions alone.

And I can't tell you whether the Board's nexus-quality coding is consistent across judges. The 93.5 percent grant rate at strong nexus versus 12.9 percent at weak nexus is too large to be entirely coding noise, but some of it almost certainly is.

What the data can tell you is what the patterns look like at the Board, what the modal denial reasons are, and where the leverage points sit. It's a map, not a forecast.

What Wins an Eczema Claim

The 2,002 cases tell a fairly consistent story. The eczema claim that wins has four things in the file.

One: body surface area documentation that captures flares, not just baseline. Photographs of flares with timestamps, dermatologist notes that record body surface area at peak severity, and a treatment record that documents the systemic medications actually prescribed. The body surface area at the C&P exam is one data point. The body surface area during flares is what determines the actual severity of the disease, and DC 7806 explicitly allows the rating to be based on extent of involvement during active disease.

Two: a treatment record that walks through systemic therapy. Topical steroids are baseline therapy and don't move the rating. Systemic therapy, oral prednisone tapers, methotrexate, dupilumab, phototherapy, does. The treatment history should be in the file with specific medications, durations, and indications. The 30 percent and 60 percent tiers are both directly tied to systemic therapy thresholds, and the file needs to show whether those thresholds are met.

Three: a lay statement that closes the snapshot gap. This is the variable that moves grant rates by 30 points in the data. The lay statement should document flare frequency, body surface area during flares (in language a non-clinician can use, "covered both forearms and elbows during the August flare"), what triggers flares, what treatments have been tried, how long flares last, and how they affect work and sleep. The Board reads these. The Board quotes these. The grant rate when they're quoted is 54.7 percent versus 24.0 percent when they're not.

Four: a nexus that engages with in-service onset or the actual toxic-exposure history. For direct connection, the service treatment records usually do most of the work. When a toxic exposure is alleged, the opinion should address that exposure and the veteran's individual risk factors; § 1119 alone is not a disease presumption. For qualifying Gulf War service, unexplained objective skin manifestations should be analyzed separately from diagnosed eczema under § 1117 and § 3.317. The 93.5 percent grant rate at strong nexus isn't an accident. It reflects files where the medical opinion explicitly walks through the in-service onset, the time course, and the chronicity of the condition.

None of this is a guarantee. The 39.9 percent grant rate at the Board is the same 39.9 percent no matter how clean your file is. But the structural variables that move outcomes are knowable, and most of them are addressable through documentation work.

Bottom Line

Eczema is the second-largest skin condition in my BVA dataset, 2,002 cases, and the grant rate is 39.9 percent, almost ten points above the overall BVA average. The rating ladder under 38 CFR § 4.118 DC 7806 has four tiers from 0 to 60 percent, with two independent paths to each tier: body surface area or systemic treatment intensity. The schedular ceiling is 60 percent; TDIU is the only path to higher compensation on eczema alone. Severity insufficient is the most common classified denial reason, which means most losing files are losing on rating evidence, not connection evidence. C&P exams are flagged inadequate 63.1 percent of the time for eczema, well above the 52 percent overall average, because the snapshot exam misses the episodic nature of the disease. Lay statements double the grant rate, 54.7 percent when the Board quotes them, 24.0 percent when it doesn't. Direct, secondary, and presumptive-coded cases all grant in the 50 to 55 percent range, with direct as the dominant path. Eczema is not a disease presumption under 38 USC § 1120 or 38 CFR § 3.320; covered toxic exposure can instead support direct development under 38 USC § 1168. The single most useful thing a veteran can do for an eczema claim is invest in a lay statement that documents flare frequency, body surface area during flares, and treatment intensity, because the C&P exam alone won't capture the condition.

Methodology and Limitations

• Data source: Outcome statistics, nexus-quality coding, denial-reason classification, C&P adequacy flags, connection-type tagging, and rating-tier distribution are drawn from Claim Raven's analysis of 101,518 condition records drawn from 49,876 Board decisions, including 2,002 eczema cases. Rating tier framework is drawn from 38 CFR § 4.118, Diagnostic Code 7806. Toxic-exposure authority is drawn from 38 USC §§ 1119, 1120, and 1168 and 38 CFR §§ 3.320, 3.320a, and 3.320b; none of those disease lists names eczema. The distinct Gulf War undiagnosed-illness framework is drawn from 38 USC § 1117 and 38 CFR § 3.317. 2026 VA disability compensation rates referenced for context, with the 100 percent single veteran rate at $4,044.91 per month.
• Sample size: 2,002 BVA decisions involving eczema, with outcomes split granted 39.9 percent (799 cases), denied 27.8 percent (557 cases), remanded 32.3 percent (646 cases). Sub-breakdowns by nexus quality, connection type, and denial reason are drawn from the same subset, with sample sizes ranging from 23 cases (aggravation connection type) to 961 cases (direct connection type).
• Classification approach: Nexus quality (strong / adequate / weak / missing / not_applicable) is coded based on the Board's treatment of the medical opinion in each decision. Denial reason is the primary classified reason the Board names; secondary reasons are not captured in the primary denial-reason variable. Lay-statement quoting is coded based on whether the decision text contains a quoted lay declaration or similar veteran/family statement.
• Limitations:
• The 2,002 eczema cases are cases that reached the BVA, not all eczema claims filed with VA. Claims granted at the regional office without appeal aren't in this dataset, and the overall VA grant rate for eczema is almost certainly higher than the 39.9 percent observed at the Board.
• Body surface area and systemic treatment intensity are not cleanly coded as separate variables in the dataset. The schedular framework discussion reflects regulatory text rather than dataset variables.
• Lay-statement quoting is coded by the Board's decision text. Whether a lay statement was submitted but not quoted is not captured separately, which is a source of measurement error in the lay-statement effect estimate.
• Rating tier distribution among grants is based on the 322 cases where a tier was clearly coded; not every grant has a clearly coded rating tier in the dataset.
• Connection type and presumptive category invocation are coded based on the Board's discussion in the decision; cases may invoke multiple theories in alternative.
• Exposure-category coding reflects theories discussed in the decision, not a conclusion that eczema was legally presumptive. A particular veteran may still establish direct service connection based on the record.
• Nexus quality is coded post-hoc by reviewing the decision text, and some hindsight bias is present in that variable.
• These observations describe BVA patterns. They are not predictions of individual outcomes.